Company
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
424 stories · page 6 of 22
"We are delighted to welcome him ... as we continue to drive and scale our growing portfolio towards key value inflexion points, support in key transactions, and drive towards exits and liquidity events"
The results from the simple blood assay were described as "impressive"
The comments follow a turnaround year for the business
"Following strong progress in 2021, PDS is now approaching significant potential value inflection points"
The board sees "substantial upside potential" through a multi-pronged growth strategy
“The company's careful planning and successful fund-raise in 2021 - in which NetScientific participated - has positioned PDS well to weather market volatility"
PDS Biotech's candidate drug PDS0101 likely safe and well tolerated in first 18 trial patients
The trial will be completed with PDS0101 alone or in combination with the checkpoint inhibitor Keytruda
PDS0101 will now progress to the full enrolment of 54 patients
London-listed NetScientific has a 5.7% interest in the US bio-tech which has announced positive preclinical data
"PDS' growing patent portfolio positions the company well for success, as the company continues to progress its clinical trials," said NetScientific boss Ilian Iliev
"We are delighted with the continued progress being made at ProAxsis with accelerated developments, new products and additional revenue streams in 2022," said chairman John Clarkson
The transaction helps diversify the company's investment portfolio
“The deal demonstrates NSCI's capital-light investment approach, is additive to NSCI's balance sheet"
"The Martlet Capital team has hit the ground running, resulting in further growth opportunities for NetScientific as we gain exposure to the excellent deal flow from the Cambridge cluster."
EpiBone creates a personalized 'scaffold' of the required replacement bone and, using a custom bioreactor and stem cells from your body, 'incubate' a new bone and remodels it as a personalised bone graft
There was cash and cash equivalents approximately $69.7mln at the end of September
Sofant is a specialist in 5G communications and an antenna developer. NetScientific has a 23.5% interest in the Edinburgh-based business
PDS Biotech has announced an agreement with the University of Georgia to license novel proteins for Versamune-based universal flu vaccine
"This investment exemplifies NetScientific's capital-light investment model into exciting technology companies," said Dr Ilian Iliev, the CEO of NetScientific
